Developer docs
API playgroundTry for free, no card

Search company profiles

Babson Diagnostics

Full company profile

uuid0000faj

Namestring
Babson Diagnostics
Legal namestring
Babson Diagnostics
Websiteurl
babsondx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Babson generates revenue through transaction fees on its BetterWay blood testing service, sold primarily via retail pharmacy distribution channels (including CVS, Walgreens, and independent pharmacies) and community-based healthcare settings. Its go-to-market combines channel partnerships through pharmacy networks and BD's healthcare system relationships with an enterprise field sales motion targeting U.S. healthcare systems for chronic disease monitoring and preventative testing use cases. Customer segments span retail pharmacy networks (primary), U.S. healthcare systems, and community-based settings including a 2026 clinical affiliation with the UT Austin School of Nursing for underserved-population outreach. The company operates exclusively in Texas and has 51-100 employees. Total disclosed funding is approximately $44.7 million across a 2020 round led by Genesis Merchant Capital and a 2021 Series B led by Emerald Development Managers with participation from Siemens Healthineers, Prism Ventures, and Lago Consulting Group.

Short descriptiontext

Babson Diagnostics is a medical technology company offering decentralized diagnostic blood testing through its BetterWay service, enabling finger-prick capillary blood collection at retail pharmacies without trained phlebotomists for patients and healthcare systems.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diagnostic blood testing, capillary blood collection, retail pharmacy diagnostics, fingertip blood testing, medical laboratory services
Industry3 codes
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAK
Point-of-Care & Decentralized Trial Testing Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHAAAG
Urinalysis & Routine Screening Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Diagnostic Blood Testing Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Blood Testing Services
TypeTransaction Fee
Description

Babson Diagnostics generates revenue through its BetterWay blood testing service, providing diagnostic blood tests at retail pharmacy locations. The service enables routine wellness screenings and chronic disease monitoring with decentralized testing capabilities.

vcaonline.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Babson Diagnostics operates the BetterWay Blood Testing service, a decentralized diagnostic testing model that uses proprietary finger-prick capillary blood collection devices and sample-handling machines to deliver venous-quality laboratory results from a few drops of blood. The service is delivered primarily through retail pharmacy locations and community-based settings without requiring trained phlebotomists, and is extended to healthcare systems via the BD MiniDraw Capillary Blood Collection System co-developed with Becton Dickinson.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Clinical studies show finger-prick tests are clinically equivalent to standard venous tests
Product overview1 text field

Babson Diagnostics offers a single unified product called BetterWay Blood Testing, a decentralized diagnostic service that combines finger-prick capillary blood collection technology with laboratory analysis to deliver venous-quality results. The service enables routine medical tests from small blood samples in pharmacies, clinics, and community settings without requiring trained phlebotomists, expanding patient access to preventative testing and chronic disease monitoring through retail pharmacy networks.

Product and service1 record
1BetterWay Blood Testing
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Five-year clinical affiliation agreement with UT Austin School of Nursing through the city-funded AMEN project. Babson Diagnostics provides training, collection devices, laboratory testing, and supervision as nursing students perform capillary blood collections during community outreach events serving underserved populations. 26 students already trained with 10 currently enrolled students having completed training and participated in three outreach events.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2024-12-01
Description

Strategic partnership to develop and distribute the BD MiniDraw Capillary Blood Collection System. BD and Babson Diagnostics are advancing decentralized diagnostic testing through finger-prick blood collection systems that deliver venous-quality results from small samples. The partnership enables routine wellness screenings and chronic disease monitoring in pharmacies and community-based settings.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers3 records
2Drawbridge Health
TypeDirect peer
Description

Drawbridge Health developed the OneDraw capillary blood collection device for decentralized diagnostic testing. It is the closest direct competitor to Babson in the finger-prick, retail-amenable sample collection category, with similar target use cases in routine screening and chronic disease monitoring.

TypeDirect peer
Description

Tasso manufactures the Tasso OnDemand and Tasso Plus capillary blood collection devices used in decentralized clinical trials and remote testing. It competes directly with Babson/BD MiniDraw in the capillary sample collection category and serves overlapping pharma, clinical research, and at-home diagnostics customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Babson Diagnostics

Diagnostic Blood Testing Servicesbabsondx.com

Babson Diagnostics is a medical technology company offering decentralized diagnostic blood testing through its BetterWay service, enabling finger-prick capillary blood collection at retail pharmacies without trained phlebotomists for patients and healthcare systems.

What Babson Diagnostics does

Babson generates revenue through transaction fees on its BetterWay blood testing service, sold primarily via retail pharmacy distribution channels (including CVS, Walgreens, and independent pharmacies) and community-based healthcare settings. Its go-to-market combines channel partnerships through pharmacy networks and BD's healthcare system relationships with an enterprise field sales motion targeting U.S. healthcare systems for chronic disease monitoring and preventative testing use cases. Customer segments span retail pharmacy networks (primary), U.S. healthcare systems, and community-based settings including a 2026 clinical affiliation with the UT Austin School of Nursing for underserved-population outreach. The company operates exclusively in Texas and has 51-100 employees. Total disclosed funding is approximately $44.7 million across a 2020 round led by Genesis Merchant Capital and a 2021 Series B led by Emerald Development Managers with participation from Siemens Healthineers, Prism Ventures, and Lago Consulting Group.

Babson Diagnostics firmographics

Firmographics
Name
Babson Diagnostics
Legal name
Babson Diagnostics
Website
https://babsondx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Babson Diagnostics is a medical technology company offering decentralized diagnostic blood testing through its BetterWay service, enabling finger-prick capillary blood collection at retail pharmacies without trained phlebotomists for patients and healthcare systems.
Ownership category
akta.pro rank

Babson Diagnostics industry classification

Industry
Product category
Diagnostic Blood Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAK
Point-of-Care & Decentralized Trial Testing Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHAAAG
Urinalysis & Routine Screening Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Diagnostic blood testing
  • Capillary blood collection
  • Retail pharmacy diagnostics
  • Fingertip blood testing
  • Medical laboratory services

Where Babson Diagnostics is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Babson Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Blood Testing Services: Babson Diagnostics generates revenue through its BetterWay blood testing service, providing diagnostic blood tests at retail pharmacy locations. The service enables routine wellness screenings and chronic disease monitoring with decentralized testing capabilities.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Babson Diagnostics product offering

Product offering

Core offering

Babson Diagnostics operates the BetterWay Blood Testing service, a decentralized diagnostic testing model that uses proprietary finger-prick capillary blood collection devices and sample-handling machines to deliver venous-quality laboratory results from a few drops of blood. The service is delivered primarily through retail pharmacy locations and community-based settings without requiring trained phlebotomists, and is extended to healthcare systems via the BD MiniDraw Capillary Blood Collection System co-developed with Becton Dickinson.

Product overview

Babson Diagnostics offers a single unified product called BetterWay Blood Testing, a decentralized diagnostic service that combines finger-prick capillary blood collection technology with laboratory analysis to deliver venous-quality results. The service enables routine medical tests from small blood samples in pharmacies, clinics, and community settings without requiring trained phlebotomists, expanding patient access to preventative testing and chronic disease monitoring through retail pharmacy networks.

Differentiator

Problem solved

Functional benefit

Products and services

  • BetterWay Blood Testing

Quantifiable outcome

  • Clinical studies show finger-prick tests are clinically equivalent to standard venous tests

Companies that use Babson Diagnostics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Babson Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Babson Diagnostics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • University of Texas at Austin School of NursingcoreStrategic or Co-development Partner · 31 March 2026Five-year clinical affiliation agreement with UT Austin School of Nursing through the city-funded AMEN project. Babson Diagnostics provides training, collection devices, laboratory testing, and supervision as nursing students perform capillary blood collections during community outreach events serving underserved populations. 26 students already trained with 10 currently enrolled students having completed training and participated in three outreach events.
  • Becton Dickinson (BD)flagshipTechnology or Integration · 1 December 2024Strategic partnership to develop and distribute the BD MiniDraw Capillary Blood Collection System. BD and Babson Diagnostics are advancing decentralized diagnostic testing through finger-prick blood collection systems that deliver venous-quality results from small samples. The partnership enables routine wellness screenings and chronic disease monitoring in pharmacies and community-based settings.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Babson Diagnostics competitors and assessment

Company assessment

Peers

Direct peers

  • Drawbridge Health: Drawbridge Health developed the OneDraw capillary blood collection device for decentralized diagnostic testing. It is the closest direct competitor to Babson in the finger-prick, retail-amenable sample collection category, with similar target use cases in routine screening and chronic disease monitoring.
  • Tasso Inc. Tasso manufactures the Tasso OnDemand and Tasso Plus capillary blood collection devices used in decentralized clinical trials and remote testing. It competes directly with Babson/BD MiniDraw in the capillary sample collection category and serves overlapping pharma, clinical research, and at-home diagnostics customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Babson Diagnostics social profiles

Digital presence

Babson Diagnostics compliance and trust

Trust signal

Compliance1 record

Babson Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Babson Diagnostics leadership team

Management profile

Number of profiles

Profiles3 records

Babson Diagnostics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Babson Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Babson Diagnostics

What does Babson Diagnostics do?

Babson Diagnostics operates the BetterWay Blood Testing service, a decentralized diagnostic testing model that uses proprietary finger-prick capillary blood collection devices and sample-handling machines to deliver venous-quality laboratory results from a few drops of blood. The service is delivered primarily through retail pharmacy locations and community-based settings without requiring trained phlebotomists, and is extended to healthcare systems via the BD MiniDraw Capillary Blood Collection System co-developed with Becton Dickinson.

Is Babson Diagnostics a public or private company?

Babson Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Babson Diagnostics founded?

Babson Diagnostics was founded in 2017. It employs 51 to 100 people.

Where is Babson Diagnostics based?

Babson Diagnostics is headquartered in Austin, United States, in the North America region.

How does Babson Diagnostics make money?

One revenue line is on record: blood Testing Services.

Who are Babson Diagnostics's main competitors?

Yourbio Health is listed as a peer. Direct peers are Drawbridge Health and Tasso Inc..

Does Babson Diagnostics have an API?

No public API is recorded for Babson Diagnostics.

What industry is Babson Diagnostics in?

Babson Diagnostics's product category is Diagnostic Blood Testing Services. Its primary akta.pro industry code is HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics), with a secondary code of HLAGAEAK, Point-of-Care & Decentralized Trial Testing Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
In VivoImpact of Theranos Still Haunts Diagnostics Companies, Say Leaders At Babson And TruvianLeaders at Babson Diagnostics and Truvian Health discussed how the Theranos scandal affected their early fundraising and investor skepticism. Babson's finger-prick testing debuted in Texas pharmacies in May 2024, while Truvian's FDA-cleared benchtop platform tests blood at the collection site. Both companies see the heightened scrutiny as a positive that raises industry standards.ExameFilme sobre Elizabeth Holmes mostra um legado que ainda assombra a biotecnologiaThe documentary 'You Can See Everything' follows Elizabeth Holmes in her final weeks before prison, released in the US last week. Despite Theranos's collapse, companies like Babson Diagnostics and Truvian Health continue developing point-of-care tests, but researchers cite sample quality and low-concentration biomarkers as hurdles. Rigorous validation remains essential for trust.FinancialContent Business PageBetterWay(TM) Blood Testing Shows How U.S. Logistics Can Help Expand Access to Healthcare at Made in America SummitBetterWay blood testing by Babson Diagnostics will host an activation at the Made in America Summit on September 10, showcasing fingertip collection without phlebotomists. The company aims to leverage existing logistics infrastructure to expand access to blood testing, with CEO Web Golinkin speaking at the event.GlobeNewswireCapillary Blood Collection Devices Market to Value USD 4.86 Billion by 2035, Expanding at an 8.26% CAGR – SNS InsiderSNS Insider released a market research report projecting the global capillary blood collection devices market to grow from USD 2.20 billion in 2025 to USD 4.86 billion by 2035, expanding at a CAGR of 8.26%, driven by rising diabetes prevalence, point-of-care diagnostics expansion, and increasing home healthcare adoption. The report highlights recent partnerships including Tasso Inc. and ARUP Laboratories validating clinical assays using capillary blood microsamples, and BD and Babson Diagnostics expanding fingertip blood collection technologies for U.S. healthcare systems. North America led the market in 2023 with a 32.2% share, while the Asia-Pacific region is identified as the fastest-growing market.TrendHunter.comDecentralized Diagnostic TestingBD and Babson Diagnostics are advancing finger-prick blood collection systems that deliver venous-quality results from small samples, enabling decentralized diagnostic testing in pharmacies and community settings without trained phlebotomists. Their technology aims to reduce operational strain on healthcare systems while expanding patient access to preventative testing and chronic disease monitoring. The article suggests this approach could reshape how diagnostic services are delivered at scale as healthcare systems increasingly prioritize convenience, accessibility, and preventative care.TrendHunter.comDecentralized Diagnostic Testing : BD and Babson DiagnosticsBD and Babson Diagnostics are advancing decentralized diagnostic testing through finger-prick blood collection systems that deliver venous-quality results from just a few drops of blood. Their technology enables routine wellness screenings and chronic disease monitoring in pharmacies, clinics, and community-based settings without requiring trained phlebotomists. This approach could reduce operational strain for healthcare providers while expanding patient access to preventative testing through retail pharmacy networks.GlobeNewswireBlood Banking Devices Market Size to Surpass USD 9.08 BN by 2034, Driven by Rising Number of Blood Banks GloballyThe global blood banking devices market is projected to grow from $3.26 billion in 2024 to $9.08 billion by 2034, a CAGR of 10.80%. Growth is driven by rising blood bank numbers, with blood processing equipment and blood banks as dominant segments, and North America leading.PharmiWeb.comBetterWay Enters Into an Affiliation Agreement with UT Austin for Capillary Blood CollectionBetterWay Blood Testing by Babson Diagnostics has entered into a five-year clinical affiliation agreement with The University of Texas at Austin School of Nursing through the city-funded AMEN project to train nursing students in BetterWay's fingertip blood collection technology. Babson Diagnostics will provide training, collection devices, laboratory testing, and supervision as students perform capillary blood collections during community outreach events serving underserved populations. The agreement integrates BetterWay technology training into select undergraduate nursing courses, with 26 students already trained and 10 currently enrolled students having completed training and participated in three outreach events.PharmiWeb.comBetterWay Blood Testing by Babson Diagnostics Achieves SOC 2 ComplianceBabson Diagnostics announced it achieved SOC 2 type I compliance for its BetterWay blood testing service, which is designed to enhance patient experience and data privacy. The compliance was verified by independent assessor A-Lign and supports its network expansion including partnerships with retail locations.